Introduction
Currently available antileukemic treatments often fail to eradicate drug-refractory quiescent leukemia stem cells (LSCs) and drugresistant proliferating LSCs and leukemia progenitor cells (LPCs). Previous reports suggest that altered DNA repair mechanisms may be responsible for enhanced survival of LSCs and/or LPCs under genotoxic stress caused by reactive oxygen species (ROS) and cytotoxic treatment (1) . Thus, leukemia cells may be highly dependent on specific DNA repair mechanisms and targeting these pathways could sensitize LSCs and LPCs to the lethality of DNA damage (2) .
DNA double-strand breaks (DSBs), the most lethal DNA lesions, are usually repaired by BRCA-mediated homologous recombination (HR) and DNA-dependent protein kinase-mediated (DNA-PKmediated) nonhomologous end-joining (NHEJ) (D-NHEJ) in proliferating cells, whereas D-NHEJ plays a major role in quiescent cells (3) . Poly(ADP)ribose polymerase 1-dependent (PARP1-dependent) NHEJ serves as a back-up (B-NHEJ) pathway in both proliferating and quiescent cells ( Figure 1A ). In addition, PARP1 may decrease or prevent accumulation of potentially lethal DSBs, either by stimulation of base excision repair and single-strand break repair and/or by facilitation of DSB repair protein MRE11-mediated recruitment of the DNA damage marker RAD51 to promote stalled replication fork restart (4, 5) .
Cancer-specific defects in DNA repair pathways create the opportunity to employ synthetic lethality, which has been applied against cancer cells harboring mutations in BRCA1 and BRCA2 by using PARP1 inhibitors (6, 7) . This finding initiated more than 100 clinical trials, which indicated that biomarkers of the response to PARP1 inhibitors reach beyond that of BRCA1/2 Quiescent and proliferating leukemia cells accumulate highly lethal DNA double-strand breaks that are repaired by 2 major mechanisms: BRCA-dependent homologous recombination and DNA-dependent protein kinase-mediated (DNA-PK-mediated) nonhomologous end-joining, whereas DNA repair pathways mediated by poly(ADP)ribose polymerase 1 (PARP1) serve as backups. Here we have designed a personalized medicine approach called gene expression and mutation analysis (GEMA) to identify BRCA-and DNA-PK-deficient leukemias either directly, using reverse transcription-quantitative PCR, microarrays, and flow cytometry, or indirectly, by the presence of oncogenes such as BCR-ABL1. DNA-PK-deficient quiescent leukemia cells and BRCA/DNA-PK-deficient proliferating leukemia cells were sensitive to PARP1 inhibitors that were administered alone or in combination with current antileukemic drugs. In conclusion, GEMA-guided targeting of PARP1 resulted in dual cellular synthetic lethality in quiescent and proliferating immature leukemia cells, and is thus a potential approach to eradicate leukemia stem and progenitor cells that are responsible for initiation and manifestation of the disease. Further, an analysis of The Cancer Genome Atlas database indicated that this personalized medicine approach could also be applied to treat numerous solid tumors from individual patients.
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PARP1 inhibitor olaparib-treated Ki67 + proliferating cells, indicating accumulation of DSBs ( Figure 2B ; BRCA1 panel, Ki67 + ). While total NHEJ was reduced, B-NHEJ was activated in the absence of XRCC6 (Figure 2A ; EJ2-GFP and EJ5-GFP, respectively). Olaparib exerted strong inhibitory activity against B-NHEJ, and also modestly diminished total NHEJ in XRCC6 -/-murine embryonic stem cells (mESCs), but did not affect repair in XRCC6 +/+ cells. This effect was associated with elevation of γ-H2AX in olaparib-treated XRCC6 -/-Ki67 + and Ki67 -cells, indicating accumulation of DSBs in proliferating and quiescent cells, respectively ( Figure 2B ; XRCC6 panels).
PARP1i reduced growth of BRCA1-mutated MDA-MB-436 human breast carcinoma cells ( Figure 2C ; BRCA1 panels) by elimination of proliferating, but not quiescent cells ( Figure 2D ; BRCA1 panels). Remarkably, PARP1i reduced the number of XRCC6 -/-cells more efficiently than XRCC6 +/+ counterparts ( Figure 2C ; XRCC6 panels), but the effect depended mainly on elimination of quiescent cells, with modest impact on proliferating cells ( Figure  2D ; XRCC6 panels).
To determine the effect of PARP1i in cells displaying dual BRCA/DNA-PK deficiency we applied 2 previously characterized models: (a) FANCA -/-XRCC6 -/-mESCs (10), and (b) the RAD54 -/-LIG4 -/-human pre-B leukemic cell line Nalm-6 (11). Cells with BRCA/DNA-PK deficiency were equally or more sensitive to olaparib and BMN673, another PARP1 inhibitor, than those displaying individual deficiencies ( Figure 3A and Supplemental Figure 1A ; supplemental material available online with this article; https:// status. In addition, PARP1 inhibitor-mediated synthetic lethality would not eradicate BRCA1/2-mutated quiescent cancer stem cells, including quiescent LSCs, which often are responsible for minimal residual disease and disease relapse (8) . We hypothesized that PARP1 inhibition (PARPi) can trigger dual cellular synthetic lethality in proliferating LSCs/LPCs and quiescent LSCs that display quantitative deficiencies in BRCA and DNA-PK pathways ( Figure 1B) .
Since inactivating mutations in BRCA and DNA-PK pathways (e.g., Fanconi anemia D1 = BRCA2 and LIG4, respectively) are rare in leukemias (9), other strategies for identifying patients with leukemias that display BRCA and DNA-PK (BRCA/DNA-PK) deficiency are needed. We developed a comprehensive gene expression and mutation analysis (GEMA) ( Figure 1C ) that identifies BRCA/ DNA-PK-deficient patients using a combination of gene expression (microarrays, reverse transcription-quantitative PCR [RTqPCR], and flow cytometry) and gene mutation (rare mutations in BRCA/DNA-PK genes and the presence of oncogenes reducing the expression of these genes) analyses to detect insufficient expression of at least 1 gene in each of the BRCA and DNA-PK pathways.
Results

PARP1i exerted dual cellular synthetic lethality by elimination of BRCA/ DNA-PK-deficient proliferating cells and DNA-PK-deficient quiescent cells. HR activity was strongly reduced in the BRCA2
-/-hamster cell line V-C8 in comparison with wild-type V79 cells (Figure 2A ; DR-GFP), which was accompanied by abundant elevation of γ-H2AX in samples from The Cancer Genome Atlas (TCGA) RNA-seq database revealed that 15 (9%) samples displayed BRCA/DNA-PK deficiency (Supplemental Figure 3D ). Gene expression analysis of our set of 172 cytogenetically normal AML samples revealed a wide range of expression levels of HR and D-NHEJ genes ( Figure 4A Figure 4B ). This finding was supported by detection of BRCA/DNA-PK-deficient AML samples in another microarray database (Supplemental Figure 4) . Downregulation of at least 1 protein in each of the BRCA and DNA-PK pathways was detected in Lin -quiescent and Ki67 + proliferating subpopulations ( Figure 3C and Supplemental Figure 1C ). These effects were accompanied by downregulation of poly(ADP-ribose) polymer formation by PARP1i (Supplemental Figure 2) .
Collectively, these data strongly suggest that PARP1i selectively inhibited B-NHEJ that promoted accumulation of lethal DSBs, resulting in dual cellular synthetic lethality through the eradication of BRCA/DNA-PK-deficient proliferating and quiescent cells.
PARP1i eradicated BRCA/DNA-PK-deficient proliferating and quiescent immature leukemia cells from individual AMLs and ALLs identified by gene expression analysis. To identify BRCA/DNA-PKdeficient individual leukemias we examined the expression of (a) HR genes, that when absent/mutated caused synthetic lethality with PARP1i (6, 7, 12) , and (b) key D-NHEJ genes (13) .
Our hypothesis was supported by detection of wide-range expression levels of BRCA1 and PRKDC (encodes for DNA-PK catalytic subunit = DNA-PKcs) in existing databases of individual patient leukemia samples (Supplemental Figure 3, A-C) . Moreover, meta-analysis of 166 acute myeloid leukemia (AML) patient To design a more diagnostically oriented approach for predicting BRCA/DNA-PK deficiency we employed RT-qPCR to quantify expression of DSB repair genes compared with a housekeeping gene such as COX6B. Our data suggest that BRCA1 and LIG4 mRNA levels lower than 1,100% and 2%, respectively, of that encoded by COX6B is predictive of BRCA/DNA-PK deficiency in 2 of 11 (18%) samples, resulting in the highest sensitivity to BMN673-driven synthetic lethality (Supplemental Figure 6 , A-C). Meta-analysis of the B cell acute lymphoblastic leukemia (B-ALL) transcriptome database supported our observation that a cohort of B-ALLs were BRCA/ DNA-PK deficient and that BRCA1 and LIG4 were frequently downregulated in these cases (Supplemental Figure 6D) .
Altogether, gene expression profiling by mRNA microarrays and by RT-qPCR followed by flow cytometry identified individual cases of BRCA/DNA-PK-deficient AMLs/ALLs, in which immature quiescent and proliferating cells were highly sensitive to PARP1i alone or in combination with the approved first-line AML therapy drug, DNR.
PARP1i exerted an antileukemic effect against BRCA/DNA-PK-deficient primary leukemia xenografts. NSG mice bearing BRCA/DNA-PK-deficient or -proficient primary leukemia xenografts (PLXs) were left untreated or treated with vehicle (control), doxorubicin (DA), BMN673, or DA + BMN673 ( Figure 7A ). Therapeutic effect was measured by detection of hCD45 + cells in deficient/proficient status of preselected samples was further validated by direct measurement of HR and NHEJ activities using specific reporter cassettes (Supplemental Figure 5A ) (14) . Both HR and NHEJ activities were downregulated in representative BRCA/ DNA-PK-deficient samples when compared with BRCA/DNA-PK-proficient counterparts (Supplemental Figure 5B) . BRCA/DNA-PK-deficient Lin -AML primary cells from individual patients were more sensitive to BMN673, and BMN673 plus daunorubicin (DNR), in comparison with BRCA/DNA-PKproficient counterparts ( Figure 5A ). LSC-enriched Lin -CD38
-AML patient cells were used to study the role of PARP1i in quiescent and proliferating LSCs because this subpopulation was the most enriched in LSCs in NSG mice (15 Figure 5B ). These cell subpopulations were much more sensitive to BMN673 alone and in combination with DNR in comparison with BRCA/DNA-PK-proficient counterparts ( Figure 5 , C and D). Moreover, BMN673 + DNR exerted a synergistic effect against BRCA/DNA-PK-deficient cells. Next, Fluidigm RT-qPCR analysis of 26 therapy-related myelodysplastic syndrome (t-MDS)/AML samples revealed that 3 samples (12%) displayed BRCA/DNA-PK deficiency (Z score < -1.5 of at least 1 gene in BRCA and DNA-PK pathways) and 11 were BRCA/DNA-PK proficient (Z score > -0.5 of all genes in BRCA and DNA-PK pathways) ( Figure 6A ). Immunofluorescent staining followed by flow cytometric analysis of BRCA/DNA-PK-deficient and BRCA/DNA-PK-proficient samples ( Figure 6A ; marked with blue and red squares, respectively) confirmed downregulation of at least 1 protein in each BRCA and DNA-PK pathway in BRCA/ DNA-PK-deficient proliferating Lin Figure 8B ). To determine the role of PARP1 in diseasemimicking settings, a tet-off SCLtTA p210BCR-ABL1-inducible mouse model of CML-CP was employed (19) . CML-CP-like disease latency was prolonged in SCLtTA p210BCR-ABL1 Parp1 -/-mice when compared with SCLtTA p210BCR-ABL1 Parp1 +/+ counterparts ( Figure 8C ). Altogether, it appears that PARP1 plays an important role in BCR-ABL1-mediated leukemogenesis.
Olaparib selectively reduced clonogenic activity of Lin -CD34
+ CML-CP immature cells in a dose-dependent manner ( Figure 8D ). Cumulative percentages from samples examined in C. *P < 0.02, **P < 0.05 in comparison with corresponding BRCA/ DNA-PK-proficient samples using Student's t test. **P < 0.03 in comparison with DNR-or BMN673-treated BRCA/DNA-PK-deficient samples using 2-way ANOVA. nt, not tested. jci.org Volume 127
The combination of TKI imatinib and PARP1 inhibitor olaparib synergistically abrogated clonogenic potential of Lin -CD34 + immature cells from CML-CP and also from more aggressive CML accelerated phase (CML-AP) patient samples ( Figure 8E) ; the effect was preceded by the accumulation of DSBs measured by γ-H2AX and induction of apoptosis detected by activation of caspase 3 ( Figure 8F ).
Olaparib also eliminated Lin -CD34 + CTV max quiescent CML-CP cells ( Figure 8G ) and imatinib plus olaparib reduced the number of LSC-enriched Lin -CD34 + CD38 -CTV max quiescent CML-CP cells ( Figure 8H ). The latter effect was accompanied by an accumulation of DSBs and annexin V-positive apoptotic cells ( Figure 8H ). Moreover, olaparib combined with imatinib or ponatinib exerted synergistic effects against BCR-ABL1-positive and BCR-ABL1(T315I)-positive B-ALL, respectively (Supplemental Figure 8) .
Meta-analyses of transcriptome databases and other reports suggested that the fusion oncoprotein AML1-ETO, but not the oncogenic partners HOXA9 and MEIS1 or the oncogenic mutant FLT3/ ITD, may negatively modulate BRCA and DNA-PK pathways (20) (21) (22) . In fact, AML1-ETO-transformed mBMCs display decreased expression of BRCA1, BRCA2, and/or KU70 proteins in comparison with HOXA9 + MEIS1-transformed cells (Supplemental Figure 9A) . Parp1 -/-mBMCs expressing AML1-ETO, but not HOXA9 + MEIS1, demonstrated reduced clonogenic activity in comparison with Parp1 +/+ counterparts (Supplemental Figure 9B ). AML1-ETO-transformed Parp1 +/+ mBMCs were highly sensitive to olaparib in comparison with cells expressing HOXA9 + MEIS1 or GFP only (Supplemental Figure 9C) Figure  9D) . Moreover, the combination of olaparib and low doses of first- 
CD38
-cells. In addition, sublethally irradiated SCID mice were injected with GFP + BCR-ABL1-positive murine leukemia cells followed by imatinib and/or BMN673 treatment ( Figure 9F ). When applied individually, imatinib or BMN673 reduced the leukemia burden in peripheral blood by 7-to 10-fold, whereas the combination exerted a synergistic effect and caused a 40-fold reduction ( Figure 9G ). This effect was associated with prolongation of the MST of leukemic mice treated with imatinib or BMN673 by 1.7-to 1.8-fold and by 4.4-fold of those treated with a combination ( Figure 9H ). Two out of 6 mice treated with imatinib + BMN673 survived more than 150 days and GFP + cells were not detected in these animals.
line therapy drug DNR exerted anticlonogenic effects against cells expressing AML1-ETO, but not against those expressing HOXA9-MEIS1 or GFP (Supplemental Figure 9E ).
PARP1i exerted an antileukemic effect in vivo against BCR-ABL1-positive CML.
To test the therapeutic potential of PARP1i in CML, sublethally irradiated NSG mice were injected with 2.5 × 10 6 Lin -CD34 + CML-CP cells obtained from 4 individual patients followed by treatment with vehicle, imatinib, olaparib, or imatinib + olaparib ( Figure 9A ). Since CML-CP cells usually do not induce lethal disease, we monitored leukemia cells in bone marrow 7 days after treatment. Imatinib or olaparib reduced the number of hCD45 + leukemia cells by 2-to 3-fold; in contrast, combination of these drugs caused a greater than 5-fold reduction of leukemia cells ( Figure 9 , B and C).
The above experiments were repeated using 1 × 10 7 Lin -CD34 + cells from a more advanced CML-AP patient; 1 week following injection mice were treated with vehicle, imatinib, BMN673, or imatinib + BMN673 ( Figure 9A ). Imatinib or BMN673 diminished the number of hCD45 + cells by 2-to 2.5-fold, whereas imatinib + BMN673 + cells (red dots) is indicated. *P ≤ 0.001, **P ≤ 0.001 in comparison with control and DA or BMN673, respectively, using Student's t test adjusted for multiple comparisons. ***P < 0.03 in comparison with DA-or BMN673-treated mice using 2-way ANOVA. (E) Survival curves and MST of PLX mice treated with diluents (green), DA (purple), BMN673 (blue), or DA + BMN673 (black). * P < 0.003, **P < 0.003 in comparison with control and DA or BMN673, respectively, using Kaplan-Meier log-rank test. jci.org Volume 127 Number 6 June 2017
The success of the PARP1 inhibitor olaparib in BRCA1-and BRCA2-deficient breast tumors has established a proof of concept for personalized cancer therapy utilizing synthetic lethality (6, 7). Tumors from individual patients predicted to be sensitive to PARP1i are usually identified either by detecting mutations in genes encoding BRCA pathway proteins, epigenetic-mediated downregulation of BRCA pathway protein expression, or by functional tests uncov-
Discussion
Quiescent and proliferating tumor cells accumulate spontaneous and treatment-induced DSBs, which are eventually repaired and thereby tolerated (18, 24, 25) . Inhibition of DSB repair has emerged as a promising antitumor treatment, especially in the context of synthetic lethality, which targets specific pathways to eradicate tumor cells while sparing normal cells (26) . mal residual disease and disease relapse (8) . Therefore, we postulated that a precision medicine-guided PARP1i-mediated dual cellular synthetic lethality approach that simultaneously targets quiescent and proliferating cancer stem and progenitor cells could be curative.
ering inefficient RAD51 foci formation (26) . While these approaches may be effective at targeting proliferating cells, they are not able to simultaneously eradicate quiescent therapy-refractory cancer stem cells (3). However, quiescent LSCs are often responsible for mini- was associated with the accumulation of DSBs and apoptosis, and was selective for BRCA/DNA-PK-deficient leukemia cells, because normal cells and BRCA/DNA-PK-proficient leukemia cells were mostly spared. Gene mutation profiling showed that leukemias expressing BCR-ABL1 (100% of CMLs and 2%-7% of ALLs in pediatric age and 20%-40% of ALLs in adults) and AML1-ETO (4%-12% of adult and 12%-30% of pediatric AMLs) are BRCA/DNA-PK deficient. The mechanisms responsible for the downregulation of genes in the BRCA/DNA-PK pathways in leukemia cells expressing BCR-ABL1 and AML1-ETO are characterized only partially. For example, BCR-ABL1 kinase inhibits BRCA1 and DNA-PKcs protein expression by suppression of translation and/or enhanced protein degradation (16, 17) . While expression of these proteins is partially restored in imatinib-treated cells, other key members of HR (RAD51) and D-NHEJ (LIG4, DCLRE1C, NHEJ1) are strongly downregulated by imatinib, thus promoting PARP1i-mediated synthetic lethality (38, 39) . The BRCA2-deficient phenotype of AML1-ETO-positive cells may depend on lack of stimulation of HOXA9 (22) .
GEMA, with emphasis on gene mutation analysis, may also be applied to identify additional oncogenes that sensitize cells to PARP1 inhibitor treatment, for example TMPRSS2-ERG-positive prostate carcinomas (DNA-PKcs deficiency), EGFR mutant-positive lung carcinomas (Fanconi anemia deficiency), EWSR1-FLI1-positive Ewing's sarcomas, and KRAS mutant-positive leukemias (40) (41) (42) (43) .
Moreover, using gene expression profiling we determined that 9%-25% of AMLs/ALLs that did not contain these oncogenes also displayed BRCA/DNA-PK deficiency. It is also plausible that additional BRCA/DNA-PK-deficient AMLs/ALLs could be identified if the list of target genes were to be expanded. For example, inclusion of Fanconi anemia genes (FANCA, FANCC, FANCG, FAN-CI), in addition to FANCD1 (also known as BRCA2), increased the pool of predicted BRCA/DNA-PK-deficient samples in TCGA database from 9% to 12%.
BRCA/DNA-PK deficiency in individual AMLs/ALLs detected by gene expression profiling may be due to epigenetic alterations. Analysis of methylome arrays revealed distinct BRCA and DNA-PK pathway methylome profiles in individual patients, which could be associated with reduced expression of methylated genes, resulting in sensitivity to PARP1i (44) . Differences in expression of heterogeneous nuclear ribonucleoproteins (e.g., hnRPN C) and miRNAs (e.g., miR-101 and miR-182) may also contribute to a BRCA/DNA-PK-deficient phenotype of individual AMLs/ALLs (45) (46) (47) .
In conclusion, we postulate that PARP1i-mediated dual cellular synthetic lethality may simultaneously eradicate BRCA/ DNA-PK-deficient quiescent and proliferating LSCs/LPCs (Supplemental Figure 10 ). In addition, we have developed a potentially novel clinically oriented personalized medicine approach, which we refer to as GEMA, for identifying patients with AMLs/ ALLs displaying BRCA/DNA-PK deficiency, which could benefit from PARP1i-induced dual cellular synthetic lethality. GEMAguided PARP1i-mediated dual cellular synthetic lethality may have a broad application for cancer treatment considering that numerous individual samples from a variety of tumor types in TCGA database may display BRCA/DNA-PK deficiency (Supplemental Figure 11 ).
As expected, PARP1 inhibitors (olaparib and BMN673) elevated lethal DSBs and promoted synthetic lethality in BRCAdeficient (BRCA1 -/-, FANCA -/-, RAD54 -/-) proliferating tumor cells. This effect is likely caused by the abrogation of PARP1-mediated stalled replication fork restart and/or inhibition of PARP1-mediated B-NHEJ (27, 28) . In addition, we show that PARP1i elevated DSBs, resulting in synthetic lethality also in DNA-PK-deficient (XRCC6 -/-, LIG4 -/-) cells; this phenomenon is supported by previous reports that combined use of DNA-PK and PARP1 inhibitors radiosensitized cells (29) and that PARP1 inhibitor-treated Lig4 -/-and Dclre1c -/-mouse embryonic fibroblasts accumulated DSBs, thereby reducing cell survival (30) .
DNA-PK-deficient proliferating cells repair DSBs by HR and/ or B-NHEJ (31); thus, PARP1i would abrogate B-NHEJ activity and also delay stalled replication fork restart and HR (32) , which is consistent with a modest but significant degree of synthetic lethality. Interestingly, the lethal effect of PARP1i was more pronounced in DNA-PK-deficient quiescent rather than proliferating cells. Quiescent cells accumulate potentially lethal DSBs, which are repaired by NHEJ (D-NHEJ and/or B-NHEJ) (25, 31) ; thus, targeting PARP1 in DNA-PK-deficient quiescent cells is synthetically lethal. This idea is supported by the observation that radiationinduced DSBs in Lig4 -/-cells reduced cell survival independently of DNA replication (30) .
We report here that olaparib and BMN673 induced synthetic lethality in both proliferating and quiescent BRCA/DNA-PKdeficient cells. This dual cellular synthetic lethality effect results from the accumulation of lethal DSBs in PARP inhibitor-treated BRCA/DNA-PK-deficient cells in S-G2/M of the cell cycle, and in PARP1 inhibitor-treated DNA-PK-deficient cells in G0/G1 phase. However, it is plausible that BRCA/DNA-PK-deficient cells with PARP1i-induced DNA damage/DSBs can continue through the G2/M checkpoint and/or spindle-assembly checkpoint, leading to the accumulation of excessive lethal DNA damage/DSBs in DNA-PK-deficient G0/G1 cells, thus resulting in cell death (33, 34) .
It has been reported that BRCA-deficient tumors with low D-NHEJ activity might be less responsive to PARPi (35) . These studies, however, relied on short-term disabling of the DNA-PK pathway by using genetic or pharmacologic approaches. BRCA/ DNA-PK-deficient cells tested here harbored long-term DNA-PK deficiency, presumably enforcing substantial remodeling of DSB repair pathways, which promotes sensitivity to PARP1i. This inference is supported by this work and other reports that BCR-ABL1 leukemia cells, which display BRCA1 and DNA-PKcs deficiencies (16, 17) , are highly sensitive to PARP1i, and that hyperactive NHEJ caused resistance to PARP1i in BRCA-deficient Fanca -/-and Fancc -/-hematopoietic stem and progenitor cells (36) . PARP1i-induced dual cellular synthetic lethality in BRCA/ DNA-PK-deficient cell lines prompted us to test PARP1i in BRCA/DNA-PK-deficient individual tumors identified by our personalized medicine strategy referred to as GEMA. Leukemias were used as testing models because their hierarchical compartments of quiescent LSCs and proliferating LSCs/LPCs are well characterized (37) . Our report suggests that PARP1i eliminated not only proliferating LSCs/LPCs, but also therapyrefractory quiescent LSCs if they displayed BRCA/DNA-PKdeficient status detected by GEMA. The lethal effect of PARP1i jci.org Volume 127 Number 6 June 2017
racycline. CML-CP-like leukemia was characterized by splenomegaly and leukocytosis associated with expansion of mature myeloid cells as described previously (18, 19 Microarray analysis. Gene expression data for 15 genes were used to select BRCA/DNA-PK-deficient and -proficient AMLs from a dataset of 172 samples arrayed on an Illumina HT-12 (supplemental data: AML gene expression levels). Peripheral blood or bone marrow samples were collected from subjects with AML after obtaining informed consent according to the procedures approved by the Research Ethics Board of the University Health Network (Toronto Princess Margaret Cancer Centre). The AML samples were cytogenetically normal. Bioinformatic analysis was performed in R. The log2 expression values for each gene were centered to a zero mean and Z scores were generated by dividing by the SD.
RT-qPCR B-ALL. Total RNA from human leukemia cells was extracted using an RNeasy Plus Micro Kit (QIAGEN) according to the manufacturer's instructions. cDNA was generated using a poly(dT) oligonucleotide and SuperScript III Reverse Transcriptase according to the manufacturer's protocol (Invitrogen). The levels of gene expression were measured using the SYBRGreenER mix (Invitrogen) with primers listed in Supplemental Table 5 . The reactions were performed using the ABI 7900HT real-time PCR system (Applied Biosystems) and analyzed with the SigmaPlot version 12.0 software program.
t-MDS/AML. Human CD34 + cells from t-MDS patients and normal controls were isolated by using magnetic bead selection (Miltenyi Biotec). Total RNA was extracted using the RNeasy Plus Micro Kit. First-strand cDNA was synthesized from 200 cells using a Superscript III First-Strand Synthesis System (Invitrogen) and preamplified for 18 cycles, and qPCR analysis performed by multiplex qPCR using the Fluidigm system and primers listed in Supplemental Table 6 . Results are expressed as the ratio to β2 microglobulin.
Detection of DSB repair proteins
Flow cytometry. The cells were fixed and permeabilized using a PerFix EXPOSE kit according to the manufacturer protocol (Beckman Coulter) followed by staining with specific antibodies: rabbit polyclonal anti-Ki67 (Abcam, ab15580), rabbit polyclonal anti-XRCC3 (Abcam, ab133736), rabbit polyclonal anti-ligase IV (Abcam, ab26039), mouse monoclonal IgG2b anti-BRCA1 (R&D Systems, MAB22101), mouse monoclonal IgG1 anti-BRCA2 (R&D Systems, MAB2476), rabbit polyclonal anti-PALB2 (Bethyl Laboratories, A301-246), rabbit polyclonal anti-KU80 (Bethyl Laboratories, A302-627A), rabbit polyclonal anti-KU70 (Bethyl Laboratories, A302-623A), rabbit polyclonal anti-DNA-PKcs (Bethyl Laboratories, A300-518A knockout mice were identified by PCR of tail snip DNA. DNA isolation and purification from mice tails were performed using the REDExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich). Genotyping for the SCLtTA and p210BCR-ABL1 transgenes and Parp1 was performed using transgene/knockout-specific primers (Operon) and 2× GoTaq polymerase Master Mix (Promega). BCR-ABL1-specific primers (forward, 5′-GAGCGTGCAGAGTGGAGGGAGAACA-3′; reverse, 5′-GGTACCAGGAGTGTTTCTCCAGACTG-3′) amplified a 500-bp fragment using amplification conditions of 40 cycles at 94°C for 45 seconds, 55°C for 1 minute, and 72°C for 1 minute. SCLtTAspecific primers (tTA, 5′-TTTCGATCTGGACATGTTGG-3′; SCL, 5′-AGAACAGAATTCAGGGTCTTCCTT-3′) yielded a 750-bp product using amplification conditions consisting of 40 cycles at 94°C for 40 seconds, 60.5°C for 1 minute, and 72°C for 1 minute. Parp1-specific primers used were: forward, 5′-CATGTTCGATGGGAAAGTCCC-3′; wild-type reverse, 5′-CCAGCGCAGCTCAGAGAAGCCA-3′; and mutant reverse, 5′-CATGTTCGATGGGAAAGTCCC-3′. The primers amplified a 112-bp fragment if wild type, a 350-bp fragment if Parp1 null, and both 112-and 350-bp fragments if heterozygous using amplification conditions consisting of 35 cycles at 94°C for 1 minute, 60°C for 1 minute, and 72°C for 3 minutes. PCR products were run in a 1.5% agarose gel containing ethidium bromide, and visualized using the Gel Doc XR+ Molecular Imager System (Bio-Rad). Mice were provided with drinking water supplemented with 0.5 g/l tetracycline hydrochloride (Sigma-Aldrich) and leukemia was induced by withdrawal of tet-jci. . Human leukemia cells were detected by anti-human CD45 antibody and leukemia stem and progenitor cells were detected by anti-human CD34 and CD38 antibodies as described previously (18) . Median survival time was determined.
Statistics. Data are expressed as mean ± SD. When conducting subgroup comparisons between 2 groups, a 2-tailed t test was used. When multiple comparisons were conducted using a t test, Bonferroni's method was used for adjusting P values for multiple testing. The synergistic effect was evaluated by 2-way ANOVA. MST of the mice ± SEM was calculated by Kaplan-Meier log-rank survival analysis. P values less than 0.05 were considered significant.
Study approval. Human studies were approved by the appropriate IRBs and met all requirements of the Declaration of Helsinki. Animal studies were approved by the Temple University IACUC. In vitro treatment. TKIs such as imatinib and ponatinib, cytotoxic drugs (DNR, DA, cytarabine), and PARP1 inhibitors olaparib and BMN673 (all from Selleckchem) were added to the indicated cells for 3 to 5 days. Murine hematopoietic/leukemia cells were maintained in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% FBS, 100 ng/ml stem cell factor (SCF), and 20 ng/ml IL-3. Primary human hematopoietic cells were incubated in IMDM supplemented with 10% FBS and growth factors (CML, AML, and normal counterparts = 100 ng/ml SCF, 20 ng/ml IL-3, 100 ng/ml Flt-3 ligand, 20 ng/ml G-CSF, 20 ng/ml IL-6; B-ALL = 10 ng/ml IL-7) followed by plating in Methocult ) leukemia and normal hematopoietic stem and progenitor cells were detected by flow cytometry using fluorochrome-conjugated anti-Lin (catalog 340546), anti-CD34 (catalog 347203 and 555821), and anti-CD38 (catalog 355790 and 555460) antibodies (all from BD Pharmingen) as described previously (18) . Cell viability was determined either by trypan blue exclusion or by annexin V staining.
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In vivo treatment. ICR SCID mice (Taconic Biosciences) were totalbody irradiated (250 cGy) and injected i.v. with 1 × 10 5 BCR-ABL1-transformed GFP + mBMCs. NSG mice (The Jackson Laboratory) were
